Display Settings:

Format

Send to:

Choose Destination

    The potential role of bisphosphonates in prostate cancer.

    Source

    Department of Urology, St George's Hospital and Medical School, London, UK. goades@sghms.ac.uk

    Abstract

    Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.

    PMID:
    12627210
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk